Tower Research Capital LLC (Trc) Gritstone Bio, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 9,554 shares of GRTS stock, worth $286. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,554
Previous 26,914
64.5%
Holding current value
$286
Previous $16,000
68.75%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding GRTS
# of Institutions
62Shares Held
35.4MCall Options Held
395KPut Options Held
132K-
Morgan Stanley New York, NY10.3MShares$308,8690.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.92MShares$147,6050.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.64MShares$139,3170.0% of portfolio
-
Versant Venture Management, LLC San Francisco, CA3.56MShares$106,8345.41% of portfolio
-
Siren, L.L.C. New York, NY3.32MShares$99,5420.1% of portfolio
About Gritstone bio, Inc.
- Ticker GRTS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,006,896
- Market Cap $2.19M
- Description
- Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...